Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03082560
Other study ID # 2016P002620
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 10, 2017
Est. completion date December 2022

Study information

Verified date January 2022
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study's Primary Objective is to design and validate a grading system for objective and accurate assessment of lichen planopilaris. Secondary Objectives: - To assess change in symptoms such as pain and itch using a Numeric Rating Scale(NRS) scores and quality of life using the Dermatology Life Quality Index (DLQI) scores - To correlate this grading system with patient skin biopsies evaluating disease activity on a microscopic level - To correlate this grading system with digital global photography and trichoscopy


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date December 2022
Est. primary completion date September 11, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Male or female subjects in general good health between the ages of 18 and 80 years old 2. Clinical and histologic diagnosis of lichen planopilaris 3. Subject is able to understand and sign informed consent 4. Subject is able to complete the study and comply with study procedures 5. Subject has no known allergy to non-toxic ink 6. Subjects should be managed by an Massachusetts General Hospital dermatologist for their lichen planopilaris for the duration of the study Exclusion Criteria: Eligible subjects will be excluded from participation if they meet any of the following criteria: 1. Presence of dermatoses that might interfere with LPP diagnosis and/or evaluation such as seborrheic dermatitis or psoriasis 2. Other selected concomitant causes of hair loss, including discoid lupus erythematosus, central centrifugal cicatricial alopecia (CCCA), telogen effluvium 3. Abnormal TSH laboratory value >1 standard deviation above normal within last year 4. Any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment 5. Any known allergy to non-toxic ink Related to Biopsy 6. History of poor wound healing or blood-clotting abnormality 7. History of keloid formation or hypertrophic scarring 8. Regular intake of high doses of aspirin or anti-coagulant medications 9. Hypersensitivity to local anesthetics 10. History of poorly controlled diabetes mellitus 11. Pregnant, nursing or planning a pregnancy

Study Design


Intervention

Diagnostic Test:
Boston Grade of Activity in Lichen Planopilaris
A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Boston Grade of Activity in Lichen Planopilaris (Boston GOAL) Design and validate a grading system for objective and accurate assessment of lichen planopilaris. 6 months
See also
  Status Clinical Trial Phase
Completed NCT04409041 - Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Enrolling by invitation NCT06202560 - Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study N/A
Not yet recruiting NCT03335228 - Platelet Rich Plasma for Frontal Fibrosing Alopecia N/A
Not yet recruiting NCT06240351 - A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) Phase 4
Not yet recruiting NCT02467101 - Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia N/A
Recruiting NCT03422640 - Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Phase 4
Completed NCT03346668 - Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia Early Phase 1
Completed NCT04342091 - Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT05332366 - A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia Phase 2